Meeting
2012 ASCO Annual Meeting
A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).
Authors
Kevin Kalinsky
Columbia University Medical Center, New York, NY
Kevin Kalinsky , Sandra J. Lee , Donald P. Lawrence , A. John Iafrate , Darrell R. Borger , Bruce Jeffrey Averbook , Ahmad A. Tarhini , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT00700882
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8522)
DOI
10.1200/jco.2012.30.15_suppl.8522
Abstract #
8522
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.
First Author: Katy K. Tsai
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
First Author: Jian Li
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren